

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address (CoMMISSIP SERVOF PATENTS AND TRADEMARKS) washington, DCC 20231 www.uspto.gov

APPLICATION NO	FILING DATE	FIRST NAMED INVENTOR	A FTORNEY DOCKET NO	CONFIRMATION NO	
09 773,365	01/31/2001	Suman Khowala	8920-000005	3998	
75	590 08/13/2002				
Harness, Dickey & Pierce, P.L.C.			EXAMINER		
P.O. Box 828 Bloomfield Hill	ls, MI 48303		MARX,	MARX, IRENE	
			ART UNIT	PAPER NUMBER	
			1651		
			DATE MAILED: 08/13/2002	1	

Please find below and/or attached an Office communication concerning this application or proceeding.

Application No. 09/773,365

Irene Marx

Applicant(s)

Office Action Summary

Examiner

Art Unit

1651

Khowala



			L	the company adopte address
n asta at 1	The MAILING DATE of this communication appears of	on the cover s	neet with	tne correspondence address
	for Reply ORTENED STATUTORY PERIOD FOR REPLY IS SET :	TO EXPIRE	3	MONTH(S) FROM
THE !	MAILING DATE OF THIS COMMUNICATION.			
	ions of time may be available under the provisions of $37\ CFR\ 1.136\ (a)$. In r g date of this communication.	no event, however,	may a reply b	e timely filed after SIX (6) MONTHS from the
If the	period for reply specified above is less than thirty (30) days, a reply within the period for reply is specified above, the maximum statutory period will apply as	e statutory minimu	m of thirty (30	days will be considered timely. more the mailing date of this communication.
 Failure 	to reply within the set or extended period for reply will, by statute, cause the	e application to bed	come ABANDO	DNED (35 U.S.C. § 133).
	ply received by the Office later than three months after the mailing date of the patent term adjustment. See 37 CFR 1.704(b).	nis communication,	even it timely	filed, may reduce any
Status				
1) 🗶	Responsive to communication(s) filed on Jun 18, 20	002		
2a) 🗶	This action is FINAL . 2b) This acti	on is non-fin	al.	
3)	Since this application is in condition for allowance e closed in accordance with the practice under Ex par	xcept for for te Quayle, 1	mal matte 935 C.D.	ers, prosecution as to the merits is 11; 453 O.G. 213.
Disposi	tion of Claims			
4) X	Claim(s) 3 and 6-12			is/are pending in the application.
4	a) Of the above, claim(s)			is/are withdrawn from consideration.
5) 🗀	Claim(s)			is/are allowed.
6) X	Claim(s) 3 and 6-12			is/are rejected.
7) 🗔	Claim(s)			is/are objected to.
8) 🗌	Claims	a	re subject	to restriction and/or election requirement.
Applica	ation Papers			
9)	The specification is objected to by the Examiner.			
10)	The drawing(s) filed on is/are	a) accep	ted or b)	objected to by the Examiner.
	Applicant may not request that any objection to the d			
11)	The proposed drawing correction filed on			
	If approved, corrected drawings are required in reply t			
12)	The oath or declaration is objected to by the Exami	ner.		
Priority	under 35 U.S.C. §§ 119 and 120			
13)	Acknowledgement is made of a claim for foreign pr	riority under	35 U.S.C.	§ 119(a)-(d) or (f).
a) [All b) Some* c) None of:			
	1. Certified copies of the priority documents hav	e been receiv	ved.	
	2. Certified copies of the priority documents hav	e been receiv	ved in App	olication No
	3. Copies of the certified copies of the priority do application from the International Bures	ocuments ha au (PCT Rule	ve been re 17.2(a)).	eceived in this National Stage
*S	see the attached detailed Office action for a list of the	e certified co	pies not r	eceived.
14)	Acknowledgement is made of a claim for domestic	priority unde	er 35 U.S.	C. § 119(e).
	The translation of the foreign language provisiona			
15)	Acknowledgement is made of a claim for domestic	priority unde	er 35 U.S.	C. §§ 120 and/or 121.
Attachm		<u>,</u> .		0.440 B Al ()
	otice of References Cited (PTO-892)			0-413) Paper No(s)
	otice of Draftsperson's Patent Drawing Review (PTO-948) formation Disclosure Statement(s) (PTO-1449) Paper No(s).		intormal Paten	it Application (PTO-152)
31 In	irormation Disclosure Statement(s) (PTO-1449) Paper No(s).	6) Other:		

Serial No. 09/773365 Art Unit 1651

The application should be reviewed for errors.

The amendment filed 6/18/02 is acknowledged. Claims 3 and 6-12 are being considered on the merits.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 3 and 6-12 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

No basis or support is found in the present specification for a concentration of any glycosylation inhibitor in the process of producing cellobiase with any *T. clypeatus* of "at least 0.05 mg/ml." The specification at page 8 recites a concentration of 0.05-5% w/v specifically for 2-deoxy-D-glucose, while original claim 3 pertain to a concentration of 0.05-5 mg/ml specifically for 2-deoxy-D-glucose using *T. clypeatus* IICB-411. It is noted that the amounts recited in the specification and claim 3 are not equivalent.

Therefore, this material raises the issue of new matter and should be deleted.

Claim 7 is rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 7 encompasses an improper Markush grouping because the term "and" is missing at the end of the listings for carbohydrates and agrowastes. Proper language is e.g. --selected from the group consisting of A,B, **AND** C--. See MPEP 2173.05(h)(a). Also the claim is

Serial No. 09/773365 Art Unit 1651

confusing in the phrase "glucose analogue D-glucosamine". The phrase "glucose analogue" appears redundant in this context and should be deleted.

The intended meaning of "dexoy nojirimycin" in claim 8 is uncertain. Is it "deoxynojirimycin"

No claim is allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL.** See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Irene Marx whose telephone number is (703) 308-2922. The examiner can normally be reached on Monday through Friday from 6:30 AM to 3:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn, can be reached on (703) 308-4743. The appropriate fax phone number for the organization where this application or proceeding is assigned is before final (703) 872-9306 and after final, (703) 872-9307.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to Customer Service whose telephone number is (703) 308-0198 or the receptionist whose telephone number is (703) 308-1235.

Irene Marx

Primary Examiner

Art Unit 1651